KYMR vs PCVX: stock comparison and AI forecast
Kymera Therapeutics, Inc. (KYMR) and Vaxcyte, Inc. (PCVX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KYMR Kymera Therapeutics, Inc.
- Market Cap
- $10.94B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
PCVX Vaxcyte, Inc.
- Market Cap
- $9.21B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- KYMR is 1.2 times larger than PCVX by market capitalization ($10.94B against $9.21B).
- PCVX carries 0.20 times debt per unit of equity, against 0.09 times for KYMR.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KYMR | PCVX |
|---|---|---|
| Market Cap | $10.94B | $9.21B |
| P/B Ratio | 6.77x | 3.70x |
| EPS | $-3.74 | $-8.06 |
| Book Value/Share | $18.91 | $16.73 |
| Revenue/Share | $0.80 | – |
| FCF/Share | $-3.38 | $-6.55 |
Profitability & Margins
| Metric | KYMR | PCVX |
|---|---|---|
| ROE | -21.6% | -46.1% |
| ROA | -19.8% | -38.4% |
| ROIC | -24.1% | -45.7% |
| Gross Margin | 0.0% | – |
| Operating Margin | -596.6% | – |
| Net Margin | -514.8% | – |
| EBT Margin | -540.5% | – |
| Tax Rate | – | 0.0% |
Financial Health
| Metric | KYMR | PCVX |
|---|---|---|
| Current Ratio | 11.13x | 4.56x |
| D/E Ratio | 0.09x | 0.20x |
| Financial Leverage | 1.09x | 1.20x |
| Interest Coverage | -3200.7x | -3390.0x |
| Working Capital | $909M | $1.05B |
Cash Flow
| Metric | KYMR | PCVX |
|---|---|---|
| Operating Cash Flow | -$288M | -$962M |
| Free Cash Flow | -$289M | -$974M |
| Capital Spending | -$1M | -$12M |
| FCF/Sales | -425.6% | – |
| CapEx/Sales | 2.0% | – |
Operational Efficiency
| Metric | KYMR | PCVX |
|---|---|---|
| Asset Turnover | 0.04x | – |
| Fixed Assets Turnover | 1.8x | – |
| Payables Period | 64 days | – |
Income Statement
| Metric | KYMR | PCVX |
|---|---|---|
| Total Revenue | $68M | – |
| Operating Income | -$405M | -$1.23B |
| Net Income | -$349M | -$1.15B |
| R&D Expense | $430M | $1.09B |
| Cost of Goods Sold | $68M | – |
Dividend & Shareholder Information
| Metric | KYMR | PCVX |
|---|---|---|
| Shares Outstanding | 85M | 149M |
KYMR vs PCVX: stock comparison and AI forecast
Which is bigger, KYMR or PCVX?
KYMR is 1.2 times larger than PCVX by market capitalization ($10.94B against $9.21B).
Which one does Intratio's AI model rank higher, KYMR or PCVX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.